title: Bevacizumab treatment for vestibular schwannomas in neurofibromatosis type two: report of two cases, including responses after prior gamma knife and vascular endothelial growth factor inhibition therapy.
abstract: OBJECTIVE
  Vestibular schwannomas are the hallmark of neurofibromatosis type two. They are difficult to treat, due to their bilateral presentation and the quest for hearing preservation. Our report describes a new treatment approach in this clinical scenario.
  
  
  METHODS
  We report two cases which confirm that bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor, causes regression of vestibular schwannomas in patients with a previous history of gamma knife radiosurgery or failed treatment with another form of vascular endothelial growth factor targeted therapy.
  
  
  CONCLUSIONS
  In 2009, Plotkin et al. reported the volumetric response of vestibular schwannomas to bevacizumab treatment, both in untreated patients and in patients previously treated with erlotinib, an epidermal growth factor receptor inhibitor. The presented cases support the use of bevacizumab to treat vestibular schwannomas. Given the extremely slow growth of these tumours, we note the rapidity of volume reduction following bevacizumab therapy.
authors: Radiotherapy Department, St Bartholomew's Hospital, London, UK. eminowicz@doctors.org.uk
authors: G K
authors: GK
authors: Eminowicz
authors: R
authors: R
authors: Raman
authors: J
authors: J
authors: Conibear
authors: P N
authors: PN
authors: Plowman
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000627:therapeutic use*; D000068258:Bevacizumab; D003287:Contrast Media; D005260:Female; D005682:Gadolinium; D046088:Hearing Loss, Unilateral / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D016518:Neurofibromatosis 2 / Q000150:complications / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D009464:Neuroma, Acoustic / Q000188:drug therapy* / Q000209:etiology / Q000532:radiotherapy / Q000601:surgery; D016634:Radiosurgery / Q000295:instrumentation; D012074:Remission Induction / Q000379:methods; D016896:Treatment Outcome; D042442:Vascular Endothelial Growth Factors
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D003287:Contrast Media; D042442:Vascular Endothelial Growth Factors; D000068258:Bevacizumab; D005682:Gadolinium